High-Pressure Contrast Media Injectors Market

Market Overview

The global high-pressure contrast media injectors market size was valued at USD 149.75 million in 2022. It is estimated to reach USD 412.63 million by 2031, growing at a CAGR of 11.9% during the forecast period (2023–2031).

Contrast media injectors are utilized to inject contrast media or contrast agents to improve blood flow and tissue perfusion. They are utilized to improve the safety of the patient during the treatment. The most efficient therapeutic device for delivering contrast is a power injector, set to administer precise amounts of contrast agent at particular flow rates. It is a component of imaging techniques that aid in treating cancer, physical injuries, strokes, heart diseases, vascular diseases, digestive disorders, and many other medical conditions. It is employed in a wide variety of therapeutic and diagnostic medical treatments.

Pressure injectors, also known as power injectors, are made up of an injector "head" into which contrast-filled syringes are placed, piston plungers that distribute the contrast from the syringes, and pressure tubing that connects the patient's syringe to their circulatory system. The operation of a pressure injector is a combination of concurrent processes in diverse scientific fields, including thermal, electricity, computing, pressure, battery operations, non-ferromagnetic metallurgy, viscosity, syringe, rheology, and catheter technology. Pressure or power injectors ensure optimal opacification and delineation of normal anatomy, covering arterial and venous anatomy and unusual lesions.

Highlights

• Consumables dominate the product segment
• Interventional cardiology dominates the application segment
• Hospital dominates the end-user segment
• North America is the highest shareholder in the global market

Market Dynamics

Global High-Pressure Contrast Media Injectors Market Drivers

Increasing Demand for Minimally Invasive Surgeries

Rapid technological advancements, improvement in the quality of patient care, and a rise in healthcare expenditure are some of the major factors contributing to the increase in demand for minimally invasive surgeries globally. In order to decrease human error and improve surgical precision and efficiency, contrast media injectors can help surgeons implant contrast agents precisely. Contrast media injectors are essential in intraoperative interventional radiology and interventional cardiology. Their use will probably be sped further by the availability of sophisticated injector systems for intraoperative imaging and diagnostics.

Faster healing, smaller incisions, lower infection risk, lessened scarring, little blood loss during the treatment, and shorter hospital stays are all benefits of minimally invasive surgeries. These advantages are expected to strengthen the market over the forecast period. Moreover, minimally invasive procedures using high-pressure contrast media injectors offer real-time imaging and high quality for surgical or diagnostic operations. This can create significant opportunities for surgeons to perform surgery in the appropriate area, augmenting the overall market.

Growing Number of Regulatory Product Approvals

The growing number of approvals for contrast media injectors by regulatory bodies, like the U.S. FDA and the EU, is predicted to contribute to market growth actively. Major manufacturers are investing heavily in creating cutting-edge solutions to meet the unmet demands of their clients, including Bracco Group, Bayer HealthCare LLC, Guerbet Group, Medtron AG, and Sino Medical-Device Technology Co., Ltd. These businesses introduce cutting-edge solutions that offer healthcare practitioners high accuracy, efficiency, and dependability. For instance, in December 2019, Bayer received the U.S. FDA's approval for expanded use of the MEDRAD Stellant Flex CT injection system, in contrast to enhanced mammography. Similarly, in February 2016, Guerbet received FDA approval for OptiOne Single-Head Contrast Delivery System, a CT contrast media injector.

Global High-Pressure Contrast Media Injectors Market Restraint

Prolonged Approval Process

Recall of products can harm a manufacturer's business and reputation. It can also negatively affect customers' loyalty to the company's products. Recalling a product raises doubts about the efficiency of new systems or devices, leading to delays or ignorance by surgeons about using similar products. For instance, in June 2016, Bayer Healthcare initiated a recall of the MEDRAD MRXerion MR Injection System owing to customer complaints describing a 4205 error message when the contrast injector was used with the 3T scanner. Such product recalls had a negative impact on customers and led to discontinuations. Therefore, frequent product recalls are predicted to hinder market growth globally.

Global High-Pressure Contrast Media Injectors Market Opportunities

Technological Advancements

Developments in high-pressure contrast media injectors, such as IT-enabled solutions for injectors, syringeless injectors, dual-head injectors, and automated injectors, have led to notable advancements in medical imaging, propelling the market. In addition, several market players are developing novel and advanced contrast media injectors to gain a competitive advantage. For instance, in November 2016, the Bracco Group announced the launch of an innovative syringeless injector, CT Exprès 3-D Contrast Media Delivery System, in the U.S. This system provides several advantages, such as the fact that there is no need to fill and clean these syringes.

Furthermore, the availability of advanced IT-enabled solutions for injectors in data management can help provide data for workflow efficiencies, improve patient safety, and analyze imaging optimization, thereby increasing their preference among end users. For instance, Bayer HealthCare LLC offers a Radimetrics Enterprise Platform, which can be integrated with Medrad MRXperion MR Injection System. This solution helps healthcare professionals document dosage, set dose reference levels, benchmark performance, and management protocols. Therefore, technological advancements are expected to create opportunities to adopt high-pressure contrast media injectors during the forecast period.

Regional Analysis

Based on region, the global high-pressure contrast media injectors market is bifurcated into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.

North America Dominates the Global Market

North America is the most significant global high-pressure contrast media injectors market shareholder and is anticipated to exhibit a CAGR of 11.21% during the forecast period. The U.S. and Canada held the largest global high-pressure contrast media injectors market share. The presence of advanced healthcare infrastructure and leading medical device manufacturers is a major factor propelling North America's market. Manufacturers are focusing on developing, commercializing, and distributing advanced products which can help cater to the needs of radiologists and surgeons. In addition, the U.S. dominated North America's high-pressure contrast media injectors market regarding revenue share. Increasing usage of high-pressure contrast media injectors in neurosurgeries and cardiac surgeries is a major factor contributing to its leading market share.

Additionally, the prevalence of several chronic diseases, such as cardiac, neurological, and orthopedic disorders, is anticipated to rise, driving the market. According to Alzheimer's Association, in 2016, approximately 5.4 million individuals in the U.S. had Alzheimer's disease, estimated to reach nearly 16 million by 2050. High-pressure contrast media injectors provide high accuracy, precision, and better outcomes during surgical procedures. Therefore, the surging prevalence of chronic illnesses is expected to boost the number of surgical procedures, propelling the demand for high-pressure contrast media injectors.

Europe is estimated to exhibit a CAGR of 11.7% over the forecast period. The European region includes Germany, the UK, France, Italy, Spain, and other countries. Germany and the UK are major contributors to Europe's market. The region is expected to grow at a lucrative pace during the forecast period because of the presence of experienced professionals and well-established healthcare infrastructure. Increasing demand for minimally invasive surgeries in Europe is another major factor anticipated to propel its market. The market is also expected to grow due to the region's relatively relaxed medical device approval standards. In addition, the U.K.'s high-pressure contrast media injectors market is expected to develop significantly owing to the increasing adoption of intraoperative imaging-based procedures, leading to surgeons' use of these injectors. High demand for advanced surgical technology and availability of advanced injectors, including mobile dual-head and syringeless injectors, are expected to drive the U.K.'s market.

Furthermore, Germany is among the major contributors to Europe's market. The rapid adoption of technologically advanced high-pressure contrast media injector-based procedures integrated with robot-assisted minimally invasive surgery is expected to promote market growth in Germany.

Japan, China, and India primarily drive the high-pressure contrast media injectors market in the Asia-Pacific. The main drivers driving this region's market are rapidly developing economies, rising healthcare awareness, and an aging population. It is anticipated that the rising senior population and the rising prevalence of chronic conditions such as neurological disorders will increase the demand for contrast media injectors. Furthermore, neurological disorders frequently start in adults over 60 and are closely linked to aging. Therefore, the high demand for advanced surgical treatment solutions for these diseases is expected to propel the demand for advanced high-pressure contrast media injectors.

Latin America comprises Brazil, Mexico, and other Latin American countries. Rapidly developing economies in this region, including Brazil and Mexico, are expected to propel the region's overall high-pressure contrast media injectors market. Latin American nations like Brazil and Mexico are popular destinations for medical tourism since there are more affordable options for high-tech medical procedures there than in North America and Europe, thereby driving the market growth.

The Middle East and Africa market is expected to grow considerably over the forecast period. Countries with significant growth rates in this region are South Africa, Saudi Arabia, and the UAE. The surging geriatric population and the increasing number of surgeries can be attributed to the expansion of the Middle East and Africa's high-pressure contrast media injectors market. With increasing government initiatives to develop healthcare infrastructure, the region is expected to witness a rise in the number of surgeries, leading to an increase in demand for high-pressure contrast media injectors. However, the shortage of skilled professionals and the inaccessibility of advanced healthcare infrastructure for performing intraoperative imaging-based surgeries involving contrast media injectors are expected to hinder Africa's market.

Segmental Analysis

The global high-pressure contrast media injectors market is segmented by product, type, application, and end-user.

Based on the product, the global high-pressure contrast media injectors market is bifurcated into injector systems and consumables. 

The consumables segment dominates the global market and is predicted to exhibit a CAGR of 11.5% over the forecast period. The consumables segment consists of syringes, tubing, and others. Due to the wide availability of technologically advanced injector systems manufactured by leading market players, the consumables segment dominated the market. The rapid adoption of minimally invasive surgeries is predicted to boost the demand for injector systems. In addition, the growing demand for consumables to maintain hygienic and safe conditions during diagnostic procedures is predicted to foster the market. Repeated purchase of these consumables for radiology, interventional cardiology, and interventional radiology is anticipated to increase the segment's share.

Based on type, the global high-pressure contrast media injectors market is segmented into single-head, dual-head, and syringeless injectors. 

The single-head injector segment owns the highest market share and is predicted to exhibit a CAGR of 11.21% during the forecast period. The most popular injectors for angiography, CT, and MRI are single-head injectors. With these injectors, contrast media is delivered using just one syringe. Angiography employs injectors with a single head. Due to its wide use and cheap average selling price, this segment accounted for the biggest revenue share. Therefore, customers in rising economies like China, India, and Brazil prioritize single-head injectors due to financial limitations. The market is also anticipated to expand significantly soon due to technological advancements and the introduction of new products. For instance, in February 2016, Guerbet received the U.S. FDA's approval for the OptiOne Single-Head Contrast Delivery System, intended to inject radiopaque contrast media during CT scan procedures.

Based on application, the global high-pressure contrast media injectors market is divided into interventional cardiology, interventional radiology, endovascular surgery, and interventional neuroradiology. 

The interventional cardiology segment is the most significant contributor to the market and is estimated to exhibit a CAGR of 11.6% over the forecast period. The increasing prevalence of cardiac ailments, including stroke, heart attack, arrhythmia, and heart valve problems, is estimated to boost segment growth. The increasing prevalence of cardiac diseases has also led to a growth in demand for interventional cardiac surgery to treat and diagnose such diseases.

Based on end-user, the global high-pressure contrast media injectors market is divided into hospitals, ambulatory surgery centers, and diagnostic centers. 

The institutional sales segment is the largest revenue contributor to the market and is expected to exhibit a CAGR of 11.9% over the forecast period. Hospitals held the highest market share because of the increasing admissions of patients suffering from cardiovascular diseases, neurological disorders, and cancer. According to the Alzheimer's Association (2016), around 47 million people worldwide have Alzheimer's disease, which is expected to reach 76 million by 2030. In addition, hospitals primarily use contrast media injectors due to their various applications in interventional radiology, radiology, and interventional cardiology. The industry is also anticipated to grow as developing nations in Asia-Pacific and Africa emphasize building their healthcare infrastructure.

Recent Developments

• June 2023- Ultravist® (iopromide)-300, -370, Bayer's iodine-based contrast agent, was authorized by the U.S. Food and Drug Administration (FDA) for contrast-enhanced mammography (CEM), making it the only contrast agent approved for this indication.
• November 2022- GE Healthcare announced its collaboration with ulrich Medical to market contrast media injectors under the brand CT Motion in the United States.